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Abstract
 
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL),
Nasu-Hakola disease, is a globally distributed recessively inherited disease. PLOSL is character-
ized by cystic bone lesions, osteoporotic features, and loss of white matter in the brain leading
to spontaneous bone fractures and profound presenile dementia. We have earlier characterized
the molecular genetic background of PLOSL by identifying mutations in two genes, 
 
DAP12
 
and 
 
TREM2
 
. DAP12 is a transmembrane adaptor protein that associates with the cell surface
receptor TREM2. The DAP12–TREM2 complex is involved in the maturation of dendritic
cells. To test a hypothesis that osteoclasts would be the cell type responsible for the bone
pathogenesis in PLOSL, we analyzed the differentiation of peripheral blood mononuclear cells
isolated from DAP12- and TREM2-deficient PLOSL patients into osteoclasts. Here we show
that loss of function mutations in 
 
DAP12
 
 and 
 
TREM2
 
 result in an inefficient and delayed
differentiation of osteoclasts with a remarkably reduced bone resorption capability in vitro.
These results indicate an important role for DAP12–TREM2 signaling complex in the differ-
entiation and function of osteoclasts.
Key words: bone diseases • central nervous system diseases • osteoporosis • monocytes • dementia
 
Introduction
 
Polycystic lipomembranous osteodysplasia with sclerosing
leukoencephalopathy (PLOSL), Nasu-Hakola disease, is a
genetically heterogeneous, recessively inherited disease.
The histological hallmarks of PLOSL are cystic bone le-
sions, osteoporotic features, and loss of white matter in the
brain. The pathological changes lead to bone fractures after
minimal trauma, severe dementia, and premature death
(1–3). We have recently identified mutations in all PLOSL
patients either in 
 
DAP12
 
 or 
 
TREM2
 
 (4, 5). DAP12 is a
transmembrane adaptor molecule that forms a complex
with several cell surface receptors depending on the cell
type, and is implicated in the activation of myeloid and NK
cells (6, 7). On the cell membrane of monocyte-derived
dendritic cells, DAP12 is expressed as a complex with
TREM2 (8, 9). The interaction between TREM2 and an
unidentified ligand results in the phosphorylation of an
immunoreceptor tyrosine-based activation motif in the cy-
toplasmic domain of DAP12. Phosphorylated DAP12 binds
the cytoplasmic protein tyrosine kinases SYK and ZAP70.
This interaction results in the activation of downstream sig-
nal transduction pathways (6, 7, 10).
Although the primary cause of PLOSL has now been
characterized, the pathogenic mechanisms behind the le-
sions in the bone and brain have remained unknown. We
have earlier proposed that the cystic bone lesions and loss
of trabecular bone in PLOSL could be caused by dysfunc-
tion of osteoclasts, the cells responsible for resorption and
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remodeling of bone (4). To test this hypothesis, we studied
the differentiation and bone resorption capability of osteo-
clasts derived from the PBMC isolated from four Finnish
and one German PLOSL patient with homozygous loss of
function mutations in 
 
DAP12
 
 (
 
TYROBP
 
 or 
 
KARAP
 
) or
 
TREM2
 
 (4, 5).
 
Materials and Methods
 
Patients. 
 
The ethical committee of National Public Health
Institute, Helsinki, Finland has approved this study. An informed
consent was obtained from all subjects. The mutation analyses
were performed as previously described (5). RT-PCR analyses of
 
TREM2
 
 of the German patient were performed using the follow-
ing primer pairs (sense and antisense): (full-length coding se-
quence) ATGGAGCCTCTCCGGCTGCT and TCACGT-
GTCTCTCAGCCCTG, (5
 
  
 
half of the coding sequence)
TCACGTGTCTCTCAGCCCTG and ATCCAGGGGGTCT-
GCCAGCA, and (3
 
  
 
half of the coding sequence) TACAAC-
CCCATGATGCGGGTC and TCACGTGTCTCTCAGC-
CCTG.
 
Induction of Osteoclasts.
 
PBMCs were isolated from buffy coat
cells over Ficoll-Paque (Amersham Biosciences). The cells were
resuspended in 
 
 
 
-MEM (GIBCO BRL), FCS, and antibiotics.
Samples of 5 
 
  
 
10
 
6 
 
cells were allowed to adhere for 1 h at 37
 
 
 
C
in a round cell culture dish 36 mm in diameter containing four
round glass coverslips 13 mm in diameter. Adherent cells were
stimulated for 1, 3, 7, 14, and 21 d with 25 ng/ml M-CSF (R&D
Systems) and 40 ng/ml RANKL (Qbiogene). The media with
cytokines was replaced twice a week.
 
Histochemistry and Immunofluorescence Stainings.
 
Staining for
tartrate-resistant acid phosphatase (TRAP) was performed using
TRAP staining kit (Sigma-Aldrich). The cytoskeletal actin was
stained using Alexa Fluor 633 phalloidin reagent (Molecular
Probes). The nuclei were visualized using DAPI reagent (Sigma-
Aldrich). The staining for cathepsin K was performed using
polyclonal anti–human cathepsin K antibody (Santa Cruz Bio-
technology, Inc.).
 
Quantitative RT-PCR Analysis.
 
Monocytes were stimulated
with M-CSF and RANKL for 1, 3, 7, and 21 d as described
above. Total RNA was isolated using TRIzol reagent (GIBCO
BRL). Quantitative RT-PCR experiments were performed us-
ing LightCycler PCR machine (Roche) as previously described
(5, 11). Serial dilutions of human 
 
DAP12
 
 (sequence data are
available from GenBank/EMBL/DDBJ under accession no.
AA481924), 
 
TREM2
 
 (sequence data are available from Gen-
Bank/EMBL/DDBJ under accession no. BF343916), 
 
TRAP
 
 (se-
quence data are available from GenBank/EMBL/DDBJ under
accession no. J04430), and calcitonin receptor (
 
CALCR
 
; se-
quence data are available from GenBank/EMBL/DDBJ under
accession no. NM_001742) cDNA cloned in a plasmid vector
were used to determine the copy number of the amplicon per
housekeeping gene cDNA copies (porphobilinogen deaminase
[
 
PBGD
 
]; sequence data are available from GenBank/EMBL/
DDBJ under accession no. M95623). Probes and human genomic
DNA were used to determine the copy number of 
 
Cathepsin K
 
,
 
PBGD
 
, and receptor activator of nuclear factor 
 
 
 
B (
 
RANK
 
). The
sequences for the PCR primers (sense and antisense, respectively)
and probes are: (
 
CALCR
 
) TCTCAGGAGTGAAAGCATTG-
CACATA and AATGCTATGACCGAATGCAGCAGTTA;
(
 
DAP12
 
) ATGGGGGGACTTGAACCC and TCATTTG-
TAATACGGCCTCTGTG; (
 
TRAP
 
) CACACAGCTGTC-
CTGGCTCAAGAA and CAGGTAGGCAGTGACCCCG-
TATGT; (
 
TREM2
 
) ATGGAGCCTCTCCGGCTGCT and
TCACGTGTCTCTCAGCCCTG; (
 
Cathepsin K
 
) CAGTGAA-
GAGGTGGTTCAGA and AGAGTCTGGGGCTCTACCTT,
(
 
Cathepsin K
 
 probe) TCCCGCAGTAATGACACCCTTT;
(
 
PBGD
 
) GGGAAACCTCAACACCCGGCT and ACCCGGT-
TGTGCCAGCCCAT, (
 
PBGD
 
 probe) ATCCTGGCAA-
CAGCTGGCCTGCA; and (
 
RANK
 
) GCAAGACCGAGATA-
GAGGAAGACAGCT and CAGGCTCAGTGAGGAACAG-
TAACTGGT, (
 
RANK
 
 probe) TGTCCATGTATTCATCT-
TCTGTGGGCATCT.
 
In Vitro Analysis of Bone Resorption. 
 
In vitro bone resorption
analysis was performed by first stimulating PBMCs from three
DAP12-deficient and four healthy individuals with M-CSF and
RANKL for 7 or 21 d. 4 
 
  
 
10
 
5 
 
cells were then transferred to a
well 7.5 mm in diameter containing a dentin slice 5 mm in diam-
eter (Immunodiagnostic Systems). Cells were incubated on den-
tin in the presence of media with cytokines (replaced twice a
week) for 7 d, fixed, and stained for TRAP. The number of
multinucleated osteoclasts and nuclei per cell was calculated using
light microscope. The cells were then brushed away and the den-
tin slices were stained with toluidine blue to visualize the resorp-
tion pits. The surface area and depth of the resorption pits were
determined using AnalySIS 3.2 software (Soft Imaging System)
and a confocal microscope, respectively.
 
Statistical Analysis.
 
Statistical analyses were performed using
GraphPad Prism 3.0 software (GraphPad Software).
 
Results and Discussion
 
DAP12- and TREM2-deficient Monocytes Show a Delayed
Differentiation into Osteoclasts.
 
Multinucleated osteoclasts
in humans are formed by the fusion of mononuclear he-
matopoietic precursor cells circulating in the monocyte
fraction (12–14). To generate osteoclasts, we stimulated the
PBMCs of four patients with 
 
DAP12
 
 mutations, one with
a 
 
TREM2
 
 mutation and four healthy individuals using a
cytokine combination consisting of M-CSF and receptor
activator of nuclear factor 
 
 
 
B ligand (RANKL), known to
induce cells with all morphological and functional charac-
teristics of osteoclasts (14, 15). All Finnish patients carried a
homozygous 5.3 kb deletion encompassing exons 1–4 of
the five exons of 
 
DAP12
 
, resulting in a total loss of expres-
sion of 
 
DAP12
 
 transcripts or polypeptide (4). The German
patient was homozygous for a conversion of nucleotide G
40 to T at the last position of exon 1 of 
 
TREM2
 
, resulting
in the creation of a premature translation termination
codon. We could not detect 
 
TREM2
 
 transcripts in the
stimulated PBMCs of the German patient in contrast to the
control cells, implying the knockout character of this mu-
tation as well (not depicted).
Induction with M-CSF and RANKL generated TRAP
 
 
 
and cathepsin K
 
  
 
osteoclasts with 10–20 nuclei in 3–7 d
from the PBMCs of healthy individuals. Remarkably, the
differentiation of DAP12- and TREM2-deficient PBMCs
into multinucleated giant cells was seriously impaired. After
7 d stimulation the number of multinucleated (three or
more nuclei) cells generated from DAP12- and TREM2-
deficient PBMCs was only 10% of that of control cells
(P 
 
  
 
0.01). A vast majority of these genetically deficientT
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multinucleated cells had three or four nuclei. The propor-
tion of cells with five or more nuclei was only 6% of the
controls (P 
 
  
 
0.01). After stimulation for 14 d the number
of genetically deficient multinucleated cells had increased
to 18% (P 
 
  
 
0.01) and the proportion of cells with five or
more nuclei increased to 20% of that of controls (P 
 
  
 
0.05;
Fig. 1 A). The multinucleation process of DAP12- and
TREM2-deficient cells was comparable to each other.
DAP12- and TREM2-deficient multinucleated cells were
cathepsin K
 
  
 
and TRAP
 
  
 
(Fig. 2). The calculated cell den-
sity of cultured DAP12- and TREM2-deficient PBMCs
was similar to the controls at all time points, indicating that
the genetically deficient cells were able to proliferate in a
similar manner as the controls. Taken together, the
DAP12–TREM2 complex mediates the differentiation of
osteoclasts. Further, in the absence of DAP12/TREM2
signaling, the fusion is very inefficient, but proceeds in the
course of time.
 
DAP12- and TREM2-deficient Osteoclastic Cells Show an
Aberrant Morphology.
 
To characterize the morphology of
the induced osteoclastic cells in more detail, we stained the
Figure 1. Impaired multinucleation and bone resorption capability of
genetically deficient osteoclasts. (A) The number of multinucleated (three
or more nuclei) DAP12- or TREM2-deficient (open bars) osteoclastic
cells per 106 adherent PBMCs calculated at day 1 was lower than that of
controls (solid bars; P    0.01) after stimulation with M-CSF and
RANKL for 7 and 14 d. (B) The total surface area per dentine slice re-
sorbed by DAP12-deficient osteoclasts (p) after incubation on dentine for
7 d was significantly reduced compared with the controls (c; P   0.01).
(C) The resorbed surface area per DAP12-deficient osteoclast (p) was
markedly smaller than that of the controls (c; P   0.05). (D) The resorp-
tion pits generated by DAP12-deficient osteoclasts were significantly
deeper compared with the controls (P   0.0001). The error bars indicate
the standard error of the mean.
Figure 2. TRAP staining of DAP12-, TREM2-deficient, and control
osteoclastic cells differentiated from PBMCs. DAP12- (A) and TREM2-
deficient (B) osteoclastic cells are intensely TRAP  and much smaller
than the control osteoclasts (C) after stimulation for 7 d. Only occasional
genetically deficient cells contain two to three nuclei. Note the numerous
processes in DAP12-deficient osteoclastic cells.T
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cells for cytoskeletal actin. An actin ring, consisting mostly
of F-actin filaments, is a functional characteristic of resorb-
ing osteoclasts and delineates the bone resorption area be-
tween an osteoclast and bone (16–18). After 7 d the F-actin
filaments in the control osteoclasts formed the typical single
large actin ring, whereas even after stimulation for 14 d the
multinucleated DAP12-deficient osteoclastic cells had sev-
eral small, unorganized granular actin clusters. The small
TREM2-deficient osteoclastic cells showed only one gran-
ular, ring-like actin staining pattern after 14 d (Fig. 3). The
transmembrane adaptor molecule DAP12 forms a complex
with several different activating receptors depending on the
cell type (7). In DAP12-deficient cells, all DAP12-associ-
ated cell surface receptors are likely to be inactive. The
slightly different morphology of actin rings in DAP12- and
TREM2-deficient osteoclastic cells could be explained by
the potential costimulatory function of other DAP12-asso-
ciated cell surface receptors in TREM2-deficient cells.
 
DAP12-deficient Osteoclastic Cells Resorb Bone.
 
To as-
sess the bone resorption capability of DAP12-deficient
multinucleated cells, we performed an in vitro bone re-
sorption assay. We first induced DAP12-deficient and con-
trol PBMCs with M-CSF and RANKL for 7 or 21 d and
then transferred the cells on dentin slices for 7 d. Multinu-
cleated DAP12-deficient cells stimulated for 7 d before
transferring on dentine slices were capable of bone resorp-
tion (Fig. 4). Although the same number of DAP12-defi-
cient and control cells were transferred per well, the total
surface area per dentine slice resorbed by DAP12-deficient
osteoclasts was reduced, being only 0.03% of that of con-
trol osteoclasts (P 
 
  
 
0.01; Fig. 1 B). Similarly, we observed
a significant difference in the average resorbed surface area
per multinucleated osteoclast between DAP12-deficient
and control osteoclasts (36 
 
 
 
m
 
2 
 
and 35,700 
 
 
 
m
 
2
 
, respec-
tively, P 
 
  
 
0.05; Fig. 1 C). Surprisingly, the surface area
per resorption pit generated by DAP12-deficient and con-
trol osteoclasts showed no difference. However, the re-
sorption pits generated by DAP12-deficient osteoclasts
were 25% deeper compared with the controls (25 
 
 
 
m and
20 
 
 
 
m, respectively, P 
 
  
 
0.0001; Fig. 1 D). Neither
DAP12-deficient nor control osteoclasts were capable of
bone resorption in resorption assays initiated after stimula-
tion for 21 d. Taken together, DAP12-deficient multinu-
cleated cells can resorb mineralized bone and they fulfill the
criteria for osteoclasts. The lower resorption rate of these
osteoclasts could either be due to an impaired actin ring
formation or to a loss of controlled cyclic changes in the
actin cytoskeleton required for osteoclast movement (17).
Figure 3. Morphological
characteristics of DAP12- and
TREM2-deficient osteoclastic
cells and control osteoclasts after
stimulation for 14 d. (A–C, same
visual field) DAP12-deficient os-
teoclastic cells are small and ca-
thepsin K   (A). Staining for
DAPI demonstrates that only oc-
casional cells have a few nuclei
(B). Phalloidin staining for actin
demonstrates numerous small
unorganized actin clusters in
DAP12-deficient osteoclastic
cells (C). (D–F, same visual field)
TREM2-deficient osteoclastic
cells are small and cathepsin K 
(D). Majority of the cells are
mononuclear (E) and show a sin-
gle granular ring-like actin stain-
ing pattern (F). (G–I, same visual
field) The control cells are large
and cathepsin K   (G), contain
multiple nuclei (H), and a single
large actin ring (I). (J) A high
magnification of two DAP12-
deficient mononuclear osteoclas-
tic cells demonstrates several
granular, unorganized actin clus-
ters. (K) A high magnification of
a mononuclear TREM2-defi-
cient cell shows a single granular
ring-like actin staining pattern.T
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Abnormal function of the actin ring or cytoskeleton in the
genetically defective osteoclasts could potentially lead to a
decrease in resorbed surface area, prolonged resorption
process, and abnormally deep resorption pits.
 
Quantitative RT-PCR Analysis.
 
To study the molecular
basis for resorption capability and osteoclastic character, we
performed a time course study of mRNA of the stimulated
cells for cathepsin K, 
 
RANK 
 
(19), 
 
TRAP,
 
 and 
 
CALCR
 
(20) using quantitative RT-PCR (Table I). 
 
Cathepsin K
 
transcripts were expressed at a very low level at days 1–3,
but became strongly up-regulated after stimulation for
7–21 d (P 
 
  
 
0.001). There was no difference between
DAP12/TREM2-deficient and control cells. Transcripts of
the gene encoding RANK, the receptor for RANKL, were
expressed in both genetically deficient and control cells af-
ter stimulation for 1 d. No significant difference was ob-
served between the patient and control cells. 
 
TRAP
 
 tran-
script level was initially low but became up-regulated after
stimulation for 3–7 d. No significant differences between
the patients and controls were observed. Both DAP12- and
TREM2-deficient cells differentiating along the osteoclas-
tic lineage expressed 
 
CALCR
 
, the receptor regulating the
resorption by osteoclasts. Reliable quantitation could not
be performed due to a low transcript level. However, there
were no obvious differences between genetically deficient
and control cells during the stimulation for 1–21 d. The
transcript levels of 
 
DAP12
 
 and 
 
TREM2 in control cells
showed a progressive increase during the stimulation for up
to 21 d. A fivefold increase in DAP12 (P   0.01) and a 39-
fold increase in TREM2 transcript level (P   0.001) was
observed between stimulations for 1 and 21 d. Taken to-
gether, the delayed differentiation and impaired resorption
function of genetically deficient osteoclasts is not due to
loss of RANK, CALCR, or TRAP expression. There were
no significant differences between DAP12/TREM2-defi-
cient and control cells, suggesting that the steady-state ex-
pression levels of the genes studied are not dependent on
DAP12 and TREM2. TREM2 polypeptide has been
shown to be undetectable in macrophages derived by stim-
ulation of monocytes for up to 14 d with M-CSF alone (9).
Thus, osteoclasts are likely to express DAP12 and TREM2
because the expression of DAP12 and TREM2 in PBMCs
differentiating along the osteoclastic lineage became pro-
gressively up-regulated parallel with the increasing number
of multinucleated osteoclasts.
DAP12- and TREM2-deficient PBMCs Migrate Efficiently.
To determine if the fusion of genetically deficient os-
teoclast precursor cells is delayed due to reduced motility
we performed a motility assay. We plated 10    106
DAP12-, TREM2-deficient, or control PBMCs per well
36 mm in diameter, each well containing four round cov-
erslips 13 mm in diameter. A cylindrical silicone object 5
mm in diameter attached to the center of each coverslip
before plating was removed after 24 h stimulation. After 7 d,
the genetically deficient cells effectively migrated to the
center of the coverslip, and multinucleated osteoclasts
were found at the center. A notable difference was ob-
served in the control cell density between the center and
surrounding areas (P   0.01), whereas there was no signif-
icant difference in the density of genetically deficient cells
between these areas (P   0.05). This implies that DAP12-
and TREM2-deficient PBMCs migrate efficiently and that
the delayed fusion of prefusion osteoclasts is not caused by
impaired motility.
The receptors and signals required for the fusion of os-
teoclast precursor cells during osteoclast maturation are not
fully understood. Our results demonstrate that DAP12/
TREM2 signaling mediates the differentiation of osteoclasts
and that DAP12/TREM2-deficiency results in an aberrant
osteoclast morphology and a severely delayed maturation
process in vitro, as indicated by the inefficient fusion and
impaired actin ring formation of the immature osteoclasts.
Kaifu et al. (21) have recently reported a defect in osteo-
clast differentiation in DAP12-deficient mice. Interestingly,
their mouse model presents a mild osteopetrosis and no
cystic bone lesions. This observation is in contradiction
Figure 4. DAP12-deficient osteoclasts are capable of bone resorption
in vitro. (A) Control osteoclasts generated long continuous resorption
pits. (B) The average surface area per resorption pit generated by DAP12-
deficient osteoclasts is similar to controls. The resorption pits generated by
genetically deficient osteoclasts are deeper compared with controls (tolui-
dine blue staining).T
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with human PLOSL where the pathological hallmarks are
cystic bone cavities and osteoporosis.
The symptoms of PLOSL appear approximately at age
20 as skeletal pain. Spontaneous fractures in the bones of
the extremities occur a few years later due to bone cavities
filled with membranous lipid material (3, 22). The lesions
are found in all limb bones, especially in the bones of the
wrists, hands, ankles and feet. In the long tubular bones,
the lesions are typically located in the distal end of the
bones. In addition, the bones show osteoporotic features,
i.e., severe loss of trabecular bone. The development of the
bone lesions is slowly progressive and the age at which the
lesions begin to develop is unknown (23). The normal av-
erage height and the macroscopic structure of the bones in
PLOSL patients, apart from the lesion cavities and trabecu-
lar bone loss, indicate that the resorptive phase of bone de-
velopment and growth is not severely affected. As ex-
pected, multinucleated, TRAP   and CD68   osteoclasts
were found in the bones of DAP12-deficient PLOSL pa-
tients. The size of osteoclasts appeared normal (not
depicted). Although the bone resorption capability of
DAP12-deficient osteoclasts was impaired in vitro, the
bones of PLOSL patients are osteoporotic rather than os-
teopetrotic, as is seen in severe osteoclastic failure (24). Our
finding of an impaired resorption capability of genetically
deficient osteoclasts in vitro is somewhat contradictory
with the local osteolytic process in PLOSL patients. Cur-
rent knowledge of DAP12/TREM2 signaling does not
provide self-evident explanations for this paradox. The lo-
cally increased bone loss in vivo could be explained by sys-
temic or local factors (endocrine, paracrine, etc.) affecting
the differentiation or activation of osteoclasts in situ.
The reason why the bone lesions in DAP12- and
TREM2-deficient PLOSL patients are found only in the
limb bones, and especially in the distal segment of the
bones, remains unclear. Bones develop either by endo-
chondral or intramembranous ossification. In endochondral
ossification a cartilage model serves as the precursor of
bone, whereas intramembranous ossification occurs with-
out an intervening cartilage precursor (25). Interestingly, all
bones affected by PLOSL are formed by endochondral os-
sification. No lesions have been found in the bones devel-
oped by intramembranous ossification (e.g., the skull, clav-
icle, and mandible; 23).
So far, the function of DAP12 and TREM2 has been
thought to be limited to transmitting activating signals to
cells of the immune system. Our findings provide, for the
first time, direct evidence that DAP12 and TREM2 in hu-
mans also play a key role in the normal functions of cells
not directly involved in immune responses. Further charac-
terization of the role of DAP12/TREM2 signaling in com-
mon disorders of bone, such as osteoporosis, should be
stimulated by our findings. Finally, despite the characteriza-
tion of a defective osteoclast maturation and function
caused by DAP12/TREM2 deficiency, understanding the
role of osteoclasts in the bone pathogenesis of PLOSL in
detail still requires additional studies in vitro and in vivo.
We thank Jari Salo for helpful comments on the manuscript and
Tuula Manninen and Mika Hukkanen for technical help.
This study was supported by the Academy of Finland, the Ulla
Hjelt Fond of the Foundation for Pediatric Research, Helsinki Bio-
medical Graduate School, the Finnish Cultural Foundation, the
Finnish Medical Foundation, the Oskar Öflund Foundation, the
Emil Aaltonen Foundation, and Maud Kuistila Foundation.
Table I. Quantitative RT-PCR Analysis of RANKL/M-CSF–stimulated PBMCs of DAP12- and TREM2-deficient and
Healthy Individuals
Time of stimulation
Gene 1 d 3 d 7 d 21 d
DAP12 (controls)a 260   132 365   95 450   161 1,304   254
TREM2 (controls)a 14   6 65   8 76   25 541   125
TRAP (controls)b 9   4 63   27 63   11 76   43
TRAP (patients) 5   1 36   8 59   16 16   4
Cathepsin K (controls)c 0.3   0.2 1   0.9 374   360 324   183
Cathepsin K (patients) 16   16 15   13 963   710 533   155
RANK (controls)b 8   3 33   17 5   3 25   15
RANK (patients) 71   29 71   13 8   3 54   11
The numbers indicate the transcript copy number per housekeeping gene copies (PBGD)   SEM. Note: DAP12, TREM2, TRAP, and cathepsin K
copy number is presented as (the absolute copy number)/(PBGD copy number), and RANK expression as 1,000   (the absolute copy number)/
(PBGD copy number).
n (controls)   4, n (patients)   5.
aDAP12 and TREM2 expression increased significantly in stimulated PBMCs (P   0.01; Bonferroni’s multiple comparison test).
bNo difference between controls and patients (P   0.05).
cA significant up-regulation in patients and controls (P   0.001; Kruskal-Wallis test), but no difference between patients and controls.T
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